Several brokerages have updated their recommendations and price targets on shares of Zynerba Pharmaceuticals (NASDAQ: ZYNE) in the last few weeks: 10/2/2017 – Zynerba Pharmaceuticals was upgraded by analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating. They now have a $17.00 price target on the stock, up previously from $4.00. 10/1/2017 […]
